Regional Citrate Anticoagulation Protocol for CRRT
Regional citrate anticoagulation should be implemented using a low-dose citrate protocol (2.5-3.0 mmol/L blood) with target post-filter ionized calcium of 0.25-0.45 mmol/L, combined with continuous monitoring of systemic ionized calcium, acid-base status, and citrate accumulation markers. 1, 2
Initial Setup and Citrate Dosing
Start with citrate infusion at 2.5 mmol/L of blood flow rather than conventional higher doses (3-5 mmol/L), as this reduces citrate-related complications without compromising circuit patency. 1 This lower initial dose provides:
- Comparable circuit life (median 51-53 hours) to higher-dose protocols 1
- Reduced risk of citrate accumulation 1
- Better achievement of target post-filter ionized calcium levels 1
The citrate solution used is typically 4% sodium citrate (40 g/L), though the FDA-labeled preparation is specifically indicated for apheresis devices. 3
Target Parameters and Titration
Post-Filter Ionized Calcium (Circuit Anticoagulation)
- Target range: 0.25-0.45 mmol/L 2, 1
- Higher targets (0.35-0.45 mmol/L) may reduce citrate-related adverse effects while maintaining circuit patency 2
- Some protocols successfully use targets up to 0.5 mmol/L with preserved filter life 4
- Titrate citrate infusion by sliding scale to maintain this target 1
Systemic Ionized Calcium (Patient Safety)
- Target range: 1.01-1.20 mmol/L 1
- Administer calcium replacement post-dialyzer, titrated by protocol to maintain systemic levels 1
- Monitor frequently to avoid hypocalcemia (4.67 times higher risk with higher citrate doses) 1
CRRT Modality Selection
CVVHDF (continuous venovenous hemodiafiltration) provides superior circuit longevity compared to CVVH or CVVHD when using calcium-containing replacement solutions. 5 Specifically:
- CVVHDF median circuit lifespan: 70 hours (IQR 65-72) 5
- CVVH median circuit lifespan: 64 hours (IQR 46-71) 5
- CVVHD median circuit lifespan: 47 hours (IQR 31.5-54) 5
- CVVHDF had lowest early circuit failure rate (12.2% vs 22.5% for CVVH and 52.5% for CVVHD) 5
Replacement/Dialysate Fluid Composition
Use bicarbonate-buffered, phosphate-containing solutions (bicarbonate 30 mmol/L, phosphate 1.2 mmol/L) to prevent metabolic complications. 4 This approach:
- Maintains appropriate acid-base balance without additional bicarbonate supplementation 4
- Prevents CRRT-related hypophosphatemia (occurs in only 30% vs 75% with phosphate-free solutions) 4
- Reduces phosphate supplementation needs from 3.4 g/day to 0.5 g/day 4
Bicarbonate is preferred over lactate as the buffer, particularly in patients with lactic acidosis or liver failure. 6
Monitoring Protocol
Frequent Monitoring (Every 4-6 Hours Initially)
- Post-filter ionized calcium - adjust citrate infusion rate 1
- Systemic ionized calcium - adjust calcium replacement 1
- Systemic pH and bicarbonate - assess for metabolic alkalosis/acidosis 4
Citrate Accumulation Surveillance
Monitor for citrate accumulation, especially in high-risk patients (chronic liver disease, post-liver transplant, elevated baseline lactate >6 mmol/L). 7 Key indicators include:
- Total calcium to ionized calcium ratio >2.5 (most sensitive marker) 7
- Widening anion gap 1
- Rising lactate levels 7
If citrate accumulation develops, reduce citrate infusion rate and increase dialysate flow - do not discontinue CRRT as accumulation typically resolves with protocol adjustments. 7
Acid-Base Management
The combination of lower citrate dose (2.5 mmol/L) with bicarbonate 30 mmol/L replacement fluid prevents metabolic alkalosis without requiring protocol modifications. 4
Vascular Access Considerations
Avoid subclavian vein access in adults due to thrombosis and late stenosis risk. 6 Prefer internal jugular or femoral access using single dual-lumen venous catheters. 6
Contraindications and High-Risk Situations
Exercise extreme caution or avoid RCA in:
- Chronic liver disease - significantly increased citrate accumulation risk 7
- Post-liver transplant patients - significantly increased citrate accumulation risk 7
- Baseline lactate >6 mmol/L - higher probability of citrate accumulation 7
- Severe lactic acidosis - impaired citrate metabolism 6
In these populations, intensify monitoring frequency and maintain lower citrate infusion rates. 7
Fluid Balance Management
Maintain negative fluid balance, particularly in patients with acute lung injury, as volume overload associates with adverse outcomes. 6 Use integrated fluid balancing systems specifically designed for CRRT rather than adapted IV pumps, which risk significant fluid balance errors. 6